Stent News and Research

RSS

A stent is a small mesh tube that’s used to treat narrowed or weakened arteries in the body.

You may have a stent placed in an artery as part of a procedure called angioplasty (AN-jee-oh-plas-tee). Angioplasty can restore blood flow through narrowed or blocked arteries. Stents help prevent arteries from becoming narrowed or blocked again in the months or years after treatment with angioplasty. You may also have a stent placed in a weakened artery to improve blood flow and to help prevent the artery from bursting.

Stents are usually made of metal mesh, but sometimes they’re made of fabric. Fabric stents, also called stent grafts, are used in larger arteries. Some stents are coated with medicines that are slowly and continuously released into the artery. These medicines help prevent the artery from becoming blocked again.

Boston Scientific, Johnson & Johnson settle breach of merger agreement lawsuit

Boston Scientific Corporation today announced the settlement of the breach of merger agreement lawsuit brought by Johnson & Johnson against Guidant Corporation, stemming from Boston Scientific's acquisition of Guidant.

18 Feb 2015

Landmark stroke studies presented at ISC, published in NEJM suggest new treatment protocol on the horizon

Research presented today at the International Stroke Conference (ISC) in Nashville, Tenn. and published online in The New England Journal of Medicine (NEJM) found that the addition of the Solitaire™ Device stent thrombectomy procedure to current pharmaceutical treatment significantly reduced disability in patients suffering stroke.

From Medtronic 13 Feb 2015

Endovascular treatment can improve patient outcomes after acute ischemic stroke

Canadian researchers have completed an international randomized controlled trial showing that a clot retrieval procedure, known as endovascular treatment (ET), can dramatically improve patient outcomes after an acute ischemic stroke. The study, led by researchers at the University of Calgary's Hotchkiss Brain Institute (HBI), shows a dramatic improvement in outcomes and a reduction in deaths from stroke.

12 Feb 2015

Landmark study heralds new era in stroke treatment worldwide

A landmark study published in the New England Journal of Medicine today heralds a new era in stroke treatment across the globe.

12 Feb 2015

New stent for treating cardiovascular disease successfully implanted in patients

A new stent for treating cardiovascular disease that incorporates a polymer invented at Rutgers, The State University of New Jersey, has been implanted in patients for the first time.

10 Feb 2015

$Study assessing efficacy of Neovasc Reducer for treatment of Refractory Angina published in NEJM$

Study assessing efficacy of Neovasc Reducer for treatment of Refractory Angina published in NEJM

Neovasc Inc. today announced that the final results from its COSIRA study assessing the efficacy and safety of the Neovasc Reducer for treatment of Refractory Angina, were published today in the New England Journal of Medicine.

5 Feb 2015

Scripps Green Hospital treats peripheral artery disease patient using new drug-coated balloon

A doctor at Scripps Green Hospital this week became the first in California to use a new drug-coated balloon to treat peripheral artery disease in a patient since regulatory approval of the IN.PACT Admiral device in January by the Food and Drug Administration.

5 Feb 2015

Clinical trial results of drug-eluting stent for peripheral arterial disease presented at LINC 2015

Historic five-year results from the world’s largest clinical trial of a drug-eluting stent for treating peripheral arterial disease (PAD) were presented last week at the Leipzig Interventional Course, in Germany. The data confirm long-term patency for patients treated with Zilver® PTX®.

From COOK MEDICAL INC. 4 Feb 2015

Magnus Life Science commemorates unique partnership with UCL to advance bio-medical research

Magnus Life Science is today celebrating its unique collaboration with University College London (UCL), one of the world's leading universities, to advance bio-medical research and bring real innovation to areas of high unmet medical need.

29 Jan 2015

EMA recommends orphan designation to Magnus Growth's novel therapy for placental insufficiency

Magnus Life Science today announces that the European Medicines Agency's Committee for Orphan Medicinal Products has reached a positive decision on recommending orphan designation to Magnus Growth's novel therapy to treat placental insufficiency.

8 Jan 2015

Researchers examine ischemic complications in patients who receive flow-diverting stents

The use of flow-diverting stents to treat intracranial aneurysms appears safe and highly successful. Recently, however, there have been reports of ischemic complications occurring in brain territories supplied by the parent artery in which the stent is placed and in brain regions fed by small arterial branches whose ostia are covered by the stent.

7 Jan 2015

Treatment for stroke: Intra-arterial treatment more effective than standard medical care for clot removal

Study results released today in The New England Journal of Medicine gave the world of stroke care more evidence that physicians are winning the battle against this debilitating disease, which affects as many as one in six people.

23 Dec 2014

Intra-arterial stroke treatment more effective than medical management with tPA, study finds

Penumbra, Inc., the market leader in intra-arterial stroke treatment, announced that an independent study published online today in the New England Journal of Medicine found that intra-arterial stroke treatment, including the company's clot extraction technology, was shown to be significantly more effective than medical management with tissue plasminogen activator (tPA), which is the current standard of care.

18 Dec 2014

Real-time radiation-exposure feedback can help medical workers adopt safer radiation practices

It's a sound that saves. A "real-time" radiation monitor that alerts by beeping in response to radiation exposure during cardiac-catheterization procedures significantly reduces the amount of exposure that medical workers receive, UT Southwestern Medical Center researchers found.

17 Dec 2014

Lombard Medical presents positive data from PYTHAGORAS PMA trial of Aorfix at VEITHsymposium

Lombard Medical, Inc., a medical device company focused on Endovascular Aneurysm Repair (EVAR) of abdominal aortic aneurysms (AAAs), today presented efficacy and safety data from the two-year follow up of the U.S. PYTHAGORAS pre-marketing approval (PMA) trial of Aorfix, the first and only endovascular stent graft with global approvals for the treatment of patients with aortic neck angulations up to 90 degrees.

21 Nov 2014

Surgical membrane delivers healing action of vitamin A

When blood vessels are damaged through surgery, it can trigger an endless cycle of scarring and repair.

21 Nov 2014

New study identifies crizotinib drug as possible new coating for drug-eluting stents

A new study has identified an FDA approved cancer drug, crizotinib, as a possible new coating for drug-eluting stents. Researchers found that crizotinib in mice helped prevent the narrowing of blood vessels after stenting without affecting the blood vessel lining.

19 Nov 2014

Health Canada to review evidence on the safety of long-term use of prescription blood-thinners

Health Canada is aware of and will be reviewing new evidence on the safety of long-term use of the prescription blood-thinners clopidogrel (Plavix) and prasugrel (Effient).

18 Nov 2014

Boston Scientific starts PLATINUM Diversity trial to evaluate Promus PREMIER Stent System

As part of its commitment to innovation and improving patient outcomes, Boston Scientific Corporation has initiated the PLATINUM Diversity trial to evaluate the clinical performance of the Promus PREMIER Everolimus-Eluting Platinum Chromium Coronary Stent System in underserved patient populations, including women and people of color.

20 Oct 2014

Johnson & Johnson's sales increase 5.1% to $18.5 billion in Q3 2014

Johnson & Johnson today announced sales of $18.5 billion for the third quarter of 2014, an increase of 5.1% as compared to the third quarter of 2013. Operational results increased 5.8% and the negative impact of currency was 0.7%. Domestic sales increased 11.6%. International sales decreased 0.3%, reflecting operational growth of 1.0% and a negative currency impact of 1.3%.

14 Oct 2014